Clinical trials in Alzheimer disease (AD) generally allow participants to continue receiving concomitant medications, including cholinesterase inhibitors (ChEIs) and memantine, if the dose is stable.
Memantine, a drug approved for Alzheimer’s disease, was associated with significant improvement in social functioning in some children and adolescents with autism spectrum disorder (ASD) without ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback